USPTO serial 87695246
SYNTHORIN
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- WEIGLE, KATHERINE CONNOLLY
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with SYNTHORIN?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Karen Lim
Karen Lim Fross Zelnick Lehrman & Zissu, P.C.151 West 42nd Street, 17th FloorNew York, NY 10036UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | protein therapeutics expressed, prepared or manufactured using a semi-synthetic organism, namely, pharmaceutical preparations for use in immunology, oncology including immuno-oncology, cardiovascular and metabolic diseases, and infectious diseases; protein therapeutics expressed, prepared or manufactured using a semi-synthetic organism, namely, proteins designed to deliver highly targeted therapeutic modulation for patients suffering from a variety of diseases, namely, cancer, autoimmune and inflammatory diseases including transplantation and delayed-type hypersensitivity, respiratory diseases, gastrointestinal diseases, cardiovascular and metabolic diseases, pathogen infections, musculoskeletal diseases, ophthalmologic and dermatologic diseases, genitourinary diseases, degenerative diseases, and orphan diseases; protein therapeutics namely, pharmaceutical preparations for use in immunology including rheumatology, oncology including immuno-oncology, pulmonology, gastroenterology, endocrinology, dermatology, urology, gynecology including fertility, infectiology including virology, ophthalmology, hepatology, neurology, and geriatrics; protein therapeutics, namely, proteins designed to deliver highly targeted therapeutic modulation for patients suffering from cancer and autoimmune disorders; Protein therapeutics, namely, proteins designed to deliver highly targeted therapeutic modulation for patients suffering from a variety of diseases, namely, therapeutic agents in the nature of cytokines, interferons, tumor cell targeting and cytolytic agents, tolerogenic and antiallergic factors, growth and differentiation factors, hormones, replacement enzymes, coagulation factors, lipid binding proteins, anti-infectives, analgesics, and tissue repair factors; non-natural protein modifications for use in connection with a variety of therapeutic areas, namely, protein arrays for medical diagnosis purposes; pharmaceutical preparations, namely, synthetic proteins for use in immunology including rheumatology, oncology including immuno-oncology, pulmonology, gastroenterology, endocrinology, dermatology, urology, gynecology including fertility, infectiology including virology, ophthalmology, hepatology, neurology, and geriatrics | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jan 31, 2022 | MAB6 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Jan 31, 2022 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| May 18, 2021 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| May 17, 2021 | EX5G | SOU EXTENSION 5 GRANTED | — |
| May 17, 2021 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| May 5, 2021 | EXT5 | SOU EXTENSION 5 FILED | — |
| May 5, 2021 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Nov 5, 2020 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Nov 3, 2020 | EX4G | SOU EXTENSION 4 GRANTED | — |
| Nov 3, 2020 | EXT4 | SOU EXTENSION 4 FILED | — |
| Nov 3, 2020 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jun 11, 2020 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jun 9, 2020 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Jun 9, 2020 | EXT3 | SOU EXTENSION 3 FILED | — |
| Jun 9, 2020 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Feb 10, 2020 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Feb 10, 2020 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Feb 7, 2020 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 7, 2020 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Dec 13, 2019 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Dec 11, 2019 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Dec 11, 2019 | EXT2 | SOU EXTENSION 2 FILED | — |
| Dec 11, 2019 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jun 20, 2019 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jun 18, 2019 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Jun 18, 2019 | EXT1 | SOU EXTENSION 1 FILED | — |
| Jun 18, 2019 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Dec 25, 2018 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Oct 30, 2018 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Oct 30, 2018 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Oct 10, 2018 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Sep 23, 2018 | ALIE | ASSIGNED TO LIE | — |
| Sep 10, 2018 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Sep 6, 2018 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Sep 6, 2018 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Sep 6, 2018 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Sep 6, 2018 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Mar 7, 2018 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 7, 2018 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 7, 2018 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 7, 2018 | DOCK | ASSIGNED TO EXAMINER | — |
| Dec 5, 2017 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Nov 25, 2017 | NWAP | NEW APPLICATION ENTERED | — |